Suscribirse

Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study - 01/03/22

Doi : 10.1016/S1470-2045(21)00752-X 
Mohamad Saad, PhD a, *, Younes Mokrab, PhD b, *, Najeeb Halabi, PhD e, *, Jingxuan Shan, PhD e, f, Rozaimi Razali, PhD b, Khalid Kunji, MSc a, Najeeb Syed, MSc c, Ramzi Temanni, PhD h, Murugan Subramanian, PhD e, g, Michele Ceccarelli, PhD i, j,

Qatar Genome Programme Research Consortium

  Members of the Qatar Genome Programme Research Consortium are listed in Supplementary Materials)
Said I Ismail, Wadha Al-Muftah, Radja Badji, Hamdi Mbarek, Dima Darwish, Tasnim Fadl, Heba Yasin, Maryem Ennaifar, Rania Abdellatif, Fatima Alkuwari, Muhammad Alvi, Yasser Al-Sarraj, Chadi Saad, Eleni Fethnou, Fatima Qafoud, Eiman Alkhayat, Nahla Afifi, Sara Tomei, Wei Liu, Stephan Lorenz, Najeeb Syed, Hakeem Almabrazi, Fazulur R Vempalli, Ramzi Temanni, Tariq Abu Saqri, Mohammedhusen Khatib, Mehshad Hamza, Tariq Abu Zaid, Ahmed El Khouly, Tushar Pathare, Shafeeq Poolat, Rashid Al-Ali, Omar Albagha, Souhaila Al-Khodor, Mashael Alshafai, Ramin Badii, Lotfi Chouchane, Xavier Estivill, Khalid Fakhro, Hamdi Mbarek, Younes Mokrab, Jithesh V Puthen, Karsten Suhre, Zohreh Tatari

Arash Rafii Tabrizi, ProfMD e, f, Davide Bedognetti, MD d, Lotfi Chouchane, ProfDSc e, f, g,
a Qatar Computing Research Institute, Hamad Bin Khalifa University, Doha, Qatar 
b Department of Human Genetics, Sidra Medicine, Doha, Qatar 
c Applied Bioinformatics Core, Integrated Genomics Services, Research Branch, Sidra Medicine, Doha, Qatar 
d Cancer Research Department, Research Branch, Sidra Medicine, Doha, Qatar 
e Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar 
f Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA 
g Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA 
h Janssen Research and Development, Paris, France 
i Department of Electrical Engineering and Information Technology (DIETI), University of Naples “Federico II”, Naples, Italy 
j Biogem, Istituto di Biologia e Genetica Molecolare, Ariano Irpino, Italy 

* Correspondence to: Professor Lotfi Chouchane, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar Weill Cornell Medicine-Qatar Education City Qatar Foundation Doha Qatar

Summary

Background

Disparities in the genetic risk of cancer among various ancestry groups and populations remain poorly defined. This challenge is even more acute for Middle Eastern populations, where the paucity of genomic data could affect the clinical potential of cancer genetic risk profiling. We used data from the phase 1 cohort of the Qatar Genome Programme to investigate genetic variation in cancer-susceptibility genes in the Qatari population.

Methods

The Qatar Genome Programme generated high-coverage genome sequencing on DNA samples collected from 6142 native Qataris, stratified into six distinct ancestry groups: general Arab, Persian, Arabian Peninsula, Admixture Arab, African, and South Asian. In this population-based, cohort study, we evaluated the performance of polygenic risk scores for the most common cancers in Qatar (breast, prostate, and colorectal cancers). Polygenic risk scores were trained in The Cancer Genome Atlas (TCGA) dataset, and their distributions were subsequently applied to the six different genetic ancestry groups of the Qatari population. Rare deleterious variants within 1218 cancer susceptibility genes were analysed, and their clinical pathogenicity was assessed by ClinVar and the CharGer computational tools.

Findings

The cohort included in this study was recruited by the Qatar Biobank between Dec 11, 2012, and June 9, 2016. The initial dataset comprised 6218 cohort participants, and whole genome sequencing quality control filtering led to a final dataset of 6142 samples. Polygenic risk score analyses of the most common cancers in Qatar showed significant differences between the six ancestry groups (p<0·0001). Qataris with Arabian Peninsula ancestry showed the lowest polygenic risk score mean for colorectal cancer (−0·41), and those of African ancestry showed the highest average for prostate cancer (0·85). Cancer-gene rare variant analysis identified 76 Qataris (1·2% of 6142 individuals in the Qatar Genome Programme cohort) carrying ClinVar pathogenic or likely pathogenic variants in clinically actionable cancer genes. Variant analysis using CharGer identified 195 individuals carriers (3·17% of the cohort). Breast cancer pathogenic variants were over-represented in Qataris of Persian origin (22 [56·4%] of 39 BRCA1/BRCA2 variant carriers) and completely absent in those of Arabian Peninsula origin.

Interpretation

We observed a high degree of heterogeneity for cancer predisposition genes and polygenic risk scores across ancestries in this population from Qatar. Stratification systems could be considered for the implementation of national cancer preventive medicine programmes.

Funding

Qatar Foundation.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2022  Elsevier Ltd. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 23 - N° 3

P. 341-352 - mars 2022 Regresar al número
Artículo precedente Artículo precedente
  • Sentinel nodes and breast cancer: an old story
  • Emmanuel Drouin, Jean-Marc Classe, Patrick Hautecoeur
| Artículo siguiente Artículo siguiente
  • Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
  • Min Yan, Quchang Ouyang, Tao Sun, Limin Niu, Jin Yang, Li Li, Yuhua Song, Chunfang Hao, Zhanhong Chen, Armando Orlandi, Naohiro Ishii, Kazuaki Takabe, Gianluca Franceschini, Francesco Ricci, Claire Verschraegen, Zhenzhen Liu, Mengwei Zhang, Huimin Lv, Liping Liu, Xiaohong Yang, Huawu Xiao, Zhichao Gao, Xiaorui Li, Fangyuan Dong, Xiuchun Chen, Jianghua Qiao, Guifang Zhang

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.